The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Commentary|Videos|January 8, 2025
Hodgkin Lymphoma: Overview and Update
Author(s)Ann S. LaCasce, MD, MMSc
Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.
Advertisement
Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
3
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
4
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
5